SEC Form 4 · accession 0001171843-18-000353
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter P. Pfreundschuh
Officer — CFO
Period of report
Sep 30, 2017
Accepted (ET)
Jan 12, 2018 · 6:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class A (ESPP)F1,F3 | Sep 30, 2017 | A | 131 | $9.10 | A | 131 | D | |
| Common Stock, Class A (ESPP)F2,F3 | Dec 31, 2017 | A | 263 | $9.10 | A | 263 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c).
- F2The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c).
- F3In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock.